These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23953228)

  • 1. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
    Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
    Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
    Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
    Haddad AQ; Kapur P; Singla N; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Sagalowsky A; Lotan Y; Margulis V
    Cancer; 2015 Jan; 121(1):43-50. PubMed ID: 25186283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.
    Darwish OM; Kapur P; Youssef RF; Bagrodia A; Belsante M; Alhalabi F; Sagalowsky AI; Lotan Y; Margulis V
    Urology; 2013 Mar; 81(3):581-6. PubMed ID: 23290145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
    Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
    Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
    Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
    Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
    Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Bergh A; Ljungberg B
    Eur Urol; 2006 Dec; 50(6):1272-7. PubMed ID: 16814458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
    Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
    Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
    Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
    Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation.
    Ku JH; Park YH; Myung JK; Moon KC; Kwak C; Kim HH
    Urol Oncol; 2011; 29(6):731-7. PubMed ID: 19914104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.